UPDATE: 3 March 2024, 8:25 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
UPDATE: 3 March 2024, 8:18 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Scientists have their eyes set on spotting Alzheimer’s early. The earlier the disease can be diagnosed, the better the chance that a combination of…
Alzheimer’s is a notoriously difficult disease to identify with certainty. By the time a patient receives a diagnosis, its pathology in the brain is…
What’s the difference between treating Alzheimer’s symptoms and modifying the disease? Despite decades of research, the underlying cause of Alzheimer’s continues to evade scientists….
UPDATE: 3 March 2024, 8:39 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Analysts had high hopes for anti-amyloid drug Aduhelm — the first Alzheimer’s treatment approved by the FDA in nearly two decades and the first…
Following the approval of the Alzheimer’s drug Aduhelm — and the litany of controversy surrounding it — one question that’s top of mind for…
The amyloid hypothesis—the idea that Alzheimer’s is caused by clumps of proteins known as beta-amyloid—remains unproven. But scientists are holding out hope that monoclonal…
UPDATE: 3 March 2024, 8:40 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Today, the experimental Eli Lilly drug donanemab received the FDA’s “breakthrough therapy designation” based on its potential to treat Alzheimer’s disease. The FDA granted…
Biogen’s aducanumab — a human antibody-based drug that targets beta-amyloid plaques, which are found in the brains of people with Alzheimer’s — has gone…
This weekend, Eli Lilly and Company presented detailed results of its phase 2 TRAILBLAZER-ALZ trial, showing that its investigational drug donanemab — monoclonal antibody…
(UPDATED Sat. March 13, 2021) In January, excitement rippled through the Alzheimer’s community with drugmaker Eli Lilly and Company’s announcement that their experimental drug…
The initial results from Eli Lilly and Co’s Phase 2 clinical trial for experimental Alzheimer’s drug donanemab provide much needed hope for the Alzheimer’s…